Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 1/2010

01-02-2010

Pathogenesis of Pulmonary Fibrosis in Systemic Sclerosis: Lessons from Interstitial Lung Disease

Authors: Kristen L. Veraldi, Eileen Hsu, Carol A. Feghali-Bostwick

Published in: Current Rheumatology Reports | Issue 1/2010

Login to get access

Abstract

Interstitial lung disease is a frequent complication of systemic sclerosis and currently is the leading cause of death. Our ability to predict which individuals are at greatest risk of developing clinically significant, progressive interstitial lung disease remains inadequate. Identification of circulating autoantibodies and other biomarkers, as well as genetic polymorphisms and aberrant gene expression, all hold promise as diagnostic and prognostic tools, as well as therapeutic targets. Many practice patterns for the diagnosis and monitoring of connective tissue disease-associated interstitial lung disease are based upon published experience with idiopathic interstitial lung diseases. Although there are likely commonalities in the pathophysiologic mechanisms and clinical progression among all fibrosing lung diseases, a better understanding of features unique to systemic sclerosis-associated interstitial lung disease is essential to the development of more effective monitoring and treatment strategies.
Literature
1.
Steen VD, Medsger TA: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437–2444.CrossRefPubMed
2.
Steen VD, Medsger TA: Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007, 66:940–944.CrossRefPubMed
3.
Fischer A, Meehan RT, Feghali-Bostwick CA, et al.: Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006, 130:976–981.CrossRefPubMed
4.
5.
Bouros D, Wells AU, Nicholson AG, et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581–1586.CrossRefPubMed
6.
Kim DS, Yoo B, Lee JS, et al.: The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:121–127.PubMed
7.
Flaherty KR, Travis WD, Colby TV, et al.: Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001, 164:1722–1727.PubMed
8.
Bjoraker JA, Ryu JH, Edwin MK, et al.: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157:199–203.PubMed
9.
Daniil ZD, Gilchrist FC, Nicholson AG, et al.: A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999, 160:899–905.PubMed
10.
Flaherty KR, Mumford JA, Murray S, et al.: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543–548.CrossRefPubMed
11.
Jegal Y, Kim DS, Shim TS, et al.: Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005, 171:639–644.CrossRefPubMed
12.
Latsi PI, du Bois RM, Nicholson AG, et al.: Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531–537.CrossRefPubMed
13.
• Zappala CJ, Latsi PI, Nicholson AG, et al.: Marginal decline in FVC is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2009 Oct 19 (Epub ahead of print). This article describes findings which suggest that subtle changes in forced vital capacity can predict prognosis and outcome in IPF.
14.
•• Park JH, Kim DS, Park IN, et al.: Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175:705–711. This article discusses one of the few studies comparing prognosis of IPF and CTD-associated ILD.CrossRefPubMed
15.
Fischer A, Swigris JJ, Groshong SD, et al.: Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008, 134:601–605.CrossRefPubMed
16.
Silver RM, Wells AU: Histopathology and bronchoalveolar lavage. Rheumatology (Oxford) 2008, 47:v62–v64.CrossRef
17.
Suga M, Iyonaga K, Okamoto T, et al.: Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000, 162:1949–1956.PubMed
18.
Andersen GN, Nilsson K, Pourazar J, et al.: Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med 2007, 101:2199–2206.CrossRefPubMed
19.
Harrison NK, Cambrey AD, Myers AR, et al.: Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (Colch) 1994, 86:141–148.
20.
Prasse A, Pechkovsky DV, Toews GB, et al.: CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56:1685–1693.CrossRefPubMed
21.
Bolster MB, Ludwicka A, Sutherland SE, et al.: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:743–751.CrossRefPubMed
22.
Antoniou KM, Mamoulaki M, Malagari K, et al.: Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007, 25:23–28.PubMed
23.
Vassallo R, Matteson E, Thomas CF Jr: Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122:1093–1096.CrossRefPubMed
24.
Raghu G, Brown KK, Costabel U, et al.: Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178:948–955.CrossRefPubMed
25.
Kohno N, Awaya Y, Oyama T, et al.: KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993, 148:637–642.PubMed
26.
Honda Y, Kuroki Y, Matsuura E, et al.: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995, 152:1860–1866.PubMed
27.
•• Fertig N, Domsic RT, Rodriguez-Reyna T, et al.: Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009, 61:958–965. This article describes a new autoantibody associated with severe progressive lung fibrosis in SSc and compares its frequency with that of other ILD-associated circulating autoantibodies.CrossRefPubMed
28.
Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al.: Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006, 33:1600–1605.PubMed
29.
Kakugawa T, Yokota S-I, Mukae H, et al.: High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis. BMC Pulm Med 2008, 8:23.CrossRefPubMed
30.
Yang Y, Fujita J, Bandoh S, et al.: Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Clin Exp Immunol 2002, 128:169–174.CrossRefPubMed
31.
• Feghali-Bostwick CA, Tsai CG, Valentine VG, et al.: Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007, 179:2592–2599. Research described in this manuscript demonstrates that, as with SSc, IPF has features of autoimmune diseases.PubMed
32.
Fujita J, Dobashi N, Ohtsuki Y, et al.: Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung 1999, 177:311–319.CrossRefPubMed
33.
Arnett FC, Cho M, Chatterjee S, et al.: Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001, 44:1359–1362.CrossRefPubMed
34.
Englert H, Small-McMahon J, Chambers P, et al.: Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999, 29:36–41.PubMed
35.
•• Feghali-Bostwick C, Medsger TA Jr, Wright TM: Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956–1963. This article describes the only study examining concordance for SSc and the presence of antinuclear antibodies in twins.CrossRefPubMed
36.
Zhou X, Tan FK, Xiong M, et al.: Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 2005, 52:3305–3314.CrossRefPubMed
37.
Dieude P, Guedj M, Wipff J, et al.: STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009, 60:2472–2479.CrossRefPubMed
38.
Coward WR, Watts K, Feghali-Bostwick CA, et al.: Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 2009, 29:4325–4339.CrossRefPubMed
39.
Glenisson W, Castronovo V, Waltregny D: Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta 2007, 1773:1572–1582.CrossRefPubMed
40.
• Wang Y, Fan PS, Kahaleh B: Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006, 54:2271–2279. This is the first published report of altered methylation in SSc.CrossRefPubMed
41.
• Sanders YY, Pardo A, Selman M, et al.: Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008, 39:610–618. This is the first published report of altered methylation in IPF.CrossRefPubMed
42.
Armanios MY, Chen JJ, Cogan JD, et al.: Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317–1326.CrossRefPubMed
43.
Tsakiri KD, Cronkhite JT, Kuan PJ, et al.: Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007, 104:7552–7557.CrossRefPubMed
44.
Ohtsuka T, Yamakage A, Yamazaki S: The polymorphism of telomerase RNA component gene in patients with systemic sclerosis. Br J Dermatol 2002, 147:250–254.CrossRefPubMed
45.
Katayama Y, Kohriyama K: Telomerase activity in peripheral blood mononuclear cells of systemic connective tissue diseases. J Rheumatol 2001, 28:288–291.PubMed
46.
• Denton CP, Merkel PA, Furst DE, et al.: Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007, 56:323–333. This study demonstrates that although TGF-β is considered a central mediator of fibrosis in SSc and related diseases, a TGF-β-blocking antibody failed to show efficacy in a clinical trial.CrossRefPubMed
47.
Aston C, Jagirdar J, Lee TC, et al.: Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995, 151:1597–1603.PubMed
48.
Hsu E, Feghali-Bostwick CA: Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. Am J Pathol 2008, 172:1580–1590.CrossRefPubMed
49.
Pilewski JM, Liu L, Henry AC, et al.: Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005, 166:399–407.PubMed
50.
•• Yasuoka H, Larregina AT, Yamaguchi Y, Feghali-Bostwick CA: Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J 2008, 2:17–22. This article describes the use of an ex vivo human skin organ culture model to assess the effect of fibrotic and antifibrotic molecules, minimize the use of animal models, and render findings more directly applicable to human disease.CrossRefPubMed
Metadata
Title
Pathogenesis of Pulmonary Fibrosis in Systemic Sclerosis: Lessons from Interstitial Lung Disease
Authors
Kristen L. Veraldi
Eileen Hsu
Carol A. Feghali-Bostwick
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 1/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-009-0071-8

Other articles of this Issue 1/2010

Current Rheumatology Reports 1/2010 Go to the issue

OriginalPaper

Impaired Fibrinolysis in the Antiphospholipid Syndrome

OriginalPaper

Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome

OriginalPaper

Intensity of Warfarin Coagulation in the Antiphospholipid Syndrome

OriginalPaper

Diagnosis and Management of Pulmonary Hypertension in Systemic Sclerosis

OriginalPaper

The Roll of Toll-like Receptors in the Antiphospholipid Syndrome

CLINICAL TRIAL REPORT

Cyclophosphamide: A Novel Treatment of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits